Tremelimumab(Imjudo) is an innovative immunotherapy drug that has shown significant potential in the treatment of hepatocellular disease and non-small cell lung disease in recent years. This article will comprehensively analyze Tremelimumab from three aspects: therapeutic effect, dosage and precautions, and provide reference for patients and medical professionals.
Therapeutic effect of Tremelimumab
It is important for patients and medical institutions to reasonably arrange treatment budgets to understand the price information of Tremelimumab.
International market price
Tremelimumab was developed by AstraZeneca in the UK and exported to many countries around the world. In the UK and some European countries, its price is strictly regulated, with a clear dose-dependent pricing strategy.
Current situation of the Chinese market
If patients need to use Tremelimumab, they need to obtain it through regular overseas medical institutions, but the price is high and they need to bear all the costs themselves. At the same time, there is no generic supply of Tremelimumab on the market.
The international market price of Tremelimumab is high, and patients need to obtain it through overseas channels, which is a heavy cost burden. The price is for reference only.
Dosage and administration of Tremelimumab
Correctly mastering the dosage and administration of Tremelimumab is the key to stabilizing the treatment effect and reducing adverse reactions.
Treatment plan for hepatocellular carcinoma
For patients with hepatocellular carcinoma weighing 30 kg or more, it is recommended to use Tremelimumab 1300 mg on the first day of the first cycle in combination with 1500 mg of durvalumab. After that, continuing to take 1500 mg of durvalumab every 4 weeks is maintenance treatment. For patients weighing less than 30 kg, the dose is adjusted according to weight.
Combination therapy for non-small cell lung disease
In the treatment of metastatic non-small cell lung disease, Tremelimumab is often used in combination with durvalumab and platinum-based chemotherapy. The specific usage is that after the first cycle of combined treatment, a single drug is administered once every 4 weeks until the disease progresses or unacceptable toxicity occurs.
The dosage and administration of Tremelimumab needs to be personalized according to the patient's weight and disease type, and the combined treatment plan needs to strictly follow the doctor's instructions.
Precautions for the use of Tremelimumab
Tremelimumab is an immunotherapy drug. Special attention should be paid to potential adverse reactions and safety issues during its use.
Monitoring and treatment of severe immune-mediated adverse reactions
Tremelimumab can cause severe or even fatal immune-mediated adverse reactions. During use, the patient's symptoms and signs should be closely monitored. Once abnormalities are found, treatment should be immediately discontinued and systemic corticosteroids should be given. For uncontrollable adverse reactions, other immunosuppressants should be considered.
Medication guidance for special populations
Pregnant women, lactating women, men and women of reproductive potential, children, and the elderly should pay special attention when using Tremelimumab. Pregnant women and lactating women should avoid using it, and women of reproductive potential should take effective contraceptive measures during treatment. The safety of children and the elderly has not been confirmed, and it needs to be carefully evaluated when used.
During the use of Tremelimumab, close attention should be paid to the patient's immune-mediated adverse reactions, and personalized medication guidance should be given to special populations to avoid potential adverse reactions.
